Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, sheds light on the FDA approval of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).
